Thomas Powles, MD, on RCC: Patient-Reported Outcomes With Belzutifan vs Everolimus

January 30, 2024 By The ASCO Post Staff

Thomas Powles, MD, of Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, and Queen Mary University of London, discusses outcomes reported by patients with previously treated renal cell carcinoma (RCC), taking part in the phase III LITESPARK-005 study. Belzutifan was associated with a prolonged time to deterioration, fewer disease-specific symptoms, and better quality of life compared with everolimus (Abstract 361).

Related Content